HLA-B*5701 frequency in Chilean HIV-infected patients and in general population

Simple item page
dc.contributor.authorPoggi, Helena
dc.contributor.authorVera, Alejandra
dc.contributor.authorLagos, Marcela
dc.contributor.authorSolari, Sandra
dc.contributor.authorRodriguez P, Luis
dc.contributor.authorPerez, Carlos M.
dc.date.accessioned2024-01-10T13:49:05Z
dc.date.available2024-01-10T13:49:05Z
dc.date.issued2010
dc.description.abstractIt has been demonstrated that HLA-B*5701 screening reduces the risk for hypersensitivity reaction to abacavir in HIV-infected patients. Since B*5701 prevalence varies among different populations, it is important to determine the carrier frequency prior to its use for the screening of HIV-infected patients. The aim of this study was to determine HLA-B*5701 carrier frequency in Chilean general population and HIV-infected patients referred for B*5701 typing. For that purpose 300 blood bank donors and 492 abacavir-naive HIV-infected patients from Chile were screened for B*5701 by a sequence specific primer PCR. We detected 14/300 (4.7%) B*57-positive individuals in the Chilean general population, 11 (3.7%) were B*5701 positive, and 3 (1%) had another subtype. All were heterozygous, thus a B*5701 allele frequency of 2% was determined. Eleven of 492 (2.2 %) HIV-patients carried a B*5701 allele. The difference between these frequencies is probably due to slow progression of HIV infection in HLA-B*5701 carriers, thus less patients would require antiretroviral therapy and B*5701 typing. Considering the usefulness of B*5701 screening, its prevalence in the Chilean general population, and the availability of a validated method, we conclude that HLA-B*5701 typing in Chilean HIV-infected patients about to initiate abacavir treatment is strongly recommended.
dc.format.extent3 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1590/S1413-86702010000500015
dc.identifier.issn1413-8670
dc.identifier.pubmedidMEDLINE:21221482
dc.identifier.urihttps://doi.org/10.1590/S1413-86702010000500015
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/79421
dc.identifier.wosidWOS:000286107300015
dc.information.autorucMedicina;Lagos M ;S/I;114715
dc.information.autorucMedicina;Perez C ;S/I;66650
dc.information.autorucMedicina;Poggi H;S/I;115999
dc.information.autorucMedicina;Rodriguez L ;S/I;99544
dc.information.autorucMedicina;Solari S ;S/I;1871
dc.information.autorucMedicina;Vera A;S/I;1006612
dc.issue.numero5
dc.language.isoen
dc.nota.accesoSin adjunto
dc.pagina.final512
dc.pagina.inicio510
dc.publisherCONTEXTO
dc.revistaBRAZILIAN JOURNAL OF INFECTIOUS DISEASES
dc.rightsregistro bibliográfico
dc.subjectHLA-B*5701
dc.subjectHIV
dc.subjectabacavir
dc.subjectChile
dc.subjectpharmacogenetics
dc.subjectHLA-B REGION
dc.subjectABACAVIR HYPERSENSITIVITY
dc.subjectGENETIC-VARIATIONS
dc.subjectASSOCIATION
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleHLA-B*5701 frequency in Chilean HIV-infected patients and in general population
dc.typeartículo
dc.volumen14
sipa.codpersvinculados114715
sipa.codpersvinculados66650
sipa.codpersvinculados115999
sipa.codpersvinculados99544
sipa.codpersvinculados1871
sipa.codpersvinculados1006612
sipa.indexWOS
sipa.indexScielo
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
HLA-B5701 frequency in Chilean HIV-infected patients and in general population.pdf
Size:
995.41 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas